Last reviewed · How we verify
NCT04921527: CHIPRO
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Phase 3 trial testing chiauranib in Ovarian Cancer in 454 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Chipscreen Biosciences, Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 454 |
| Start date | 20 December 2021 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 July 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- chiauranib — full drug profile →
- Placebo
- Paclitaxel — full drug profile →
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
- Relapsed or Refractory — all drugs for Relapsed or Refractory →
- Chiauranib — all drugs for Chiauranib →
- Paclitaxel — all drugs for Paclitaxel →
Sponsor
Chipscreen Biosciences, Ltd. — full company profile →
Who can join
Adults 18 to 70, female only, with Ovarian Cancer or Relapsed or Refractory. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized, double-blind, 2-arm study will evaluate the efficacy and safety of Chiauranib plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with Platinum-refractory or Platinum-resistant Recurrent ovarian cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting of TAMs: can we be more clever than cancer cells?
Kzhyshkowska J, Shen J, Larionova I. · · 2024 · cited 79× · PMID 39516356 · DOI 10.1038/s41423-024-01232-z -
Aurora B Inhibitors as Cancer Therapeutics.
Kovacs AH, Zhao D, Hou J. · · 2023 · cited 32× · PMID 37110619 · DOI 10.3390/molecules28083385 -
Macrophages as Promising Carriers for Nanoparticle Delivery in Anticancer Therapy.
Wróblewska A, Szczygieł A, Szermer-Olearnik B, Pajtasz-Piasecka E. · · 2023 · cited 31× · PMID 37576466 · DOI 10.2147/ijn.s421173 -
Research Advances in Clinical Applications, Anticancer Mechanism, Total Chemical Synthesis, Semi-Synthesis and Biosynthesis of Paclitaxel.
Zhang S, Ye T, Liu Y, Hou G, et al · · 2023 · cited 26× · PMID 38005238 · DOI 10.3390/molecules28227517 -
Overcoming the challenges of drug development in platinum-resistant ovarian cancer.
Eskander RN, Moore KN, Monk BJ, Herzog TJ, et al · · 2023 · cited 24× · PMID 37916177 · DOI 10.3389/fonc.2023.1258228 -
Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises.
Skorda A, Bay ML, Hautaniemi S, Lahtinen A, et al · · 2022 · cited 24× · PMID 36551745 · DOI 10.3390/cancers14246257 -
Tumour-associated macrophages: versatile players in the tumour microenvironment.
Ji ZZ, Chan MK, Chan AS, Leung KT, et al · · 2023 · cited 18× · PMID 37965573 · DOI 10.3389/fcell.2023.1261749 -
Natural products for enhancing the sensitivity or decreasing the adverse effects of anticancer drugs through regulating the redox balance.
Sun Y, Li Q, Huang Y, Yang Z, et al · · 2024 · cited 7× · PMID 39164783 · DOI 10.1186/s13020-024-00982-2
Verify or expand the search:
- PubMed search for NCT04921527
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of chiauranib
Trials testing the same drug.
- NCT03901118 — Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer · Phase 2 · completed
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Chipscreen Biosciences, Ltd. trials
Trials by the same sponsor.
- NCT07511010 — Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets · Phase 1 · not yet recruiting
- NCT07519265 — Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets · NA · not yet recruiting
- NCT07412015 — Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets · NA · not yet recruiting
- NCT07445295 — Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenoca · Phase 3 · not yet recruiting
- NCT07129382 — A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04921527 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chipscreen Biosciences, Ltd.
- Last refreshed: 18 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04921527.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing